Verastem Oncology’s KRAS G12D inhibitor earns FDA Fast Track for non-small cell lung cancer

Boston-based Verastem Oncology (Nasdaq: VSTM) announced receipt of US FDA Fast Track Designation for VS-7375, an oral selective KRAS G12D (ON/OFF) inhibitor, for the treatment of adult patients with KRAS G12D-mutated unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received platinum-based chemotherapy and an anti-PD-(L)1 antibody. The designation marks the second Fast Track award for VS-7375, following one granted in July 2025 for KRAS G12D-mutated locally advanced or metastatic pancreatic cancer.

Fast Track Designation enables more frequent FDA interactions, rolling NDA/BLA review, and eligibility for Priority Review and Accelerated Approval, provided the program continues to demonstrate activity in a serious condition with unmet need. The designation also places Verastem among a small group of companies racing to develop the first approved therapy targeting KRAS G12D, one of the most common yet historically undruggable KRAS mutations.

VS-7375 binds both the active (GTP-bound, ON) and inactive (GDP-bound, OFF) conformational states of the KRAS G12D oncoprotein. This differentiates it from inhibitors that target only the OFF state, with the rationale that dual-state engagement may more completely suppress downstream RAS/MAPK signaling and restrict tumor growth. The compound is administered orally once daily.

The NSCLC indication addresses approximately 8,000 patients diagnosed annually in the US with KRAS G12D-mutant disease, representing roughly 5% of NSCLC cases. No FDA-approved therapy currently exists that specifically targets KRAS G12D mutations in any tumor type. Patients with this mutation demonstrate reduced responses to standard systemic regimens and carry a poor prognosis relative to other NSCLC molecular subtypes.

The clinical program supporting the designation centers on TARGET-D 101, a Phase I/II dose escalation, dose expansion, and combination trial initiated in June 2025 in patients with advanced KRAS G12D-mutant solid tumors, including NSCLC, pancreatic, and colorectal cancers. Early clinical data reported in March 2026 showed no dose-limiting toxicities and a generally favorable tolerability profile.

The AllSci BriefSystematic R&D and deal news. Daily.

Verastem has also initiated TARGET-D 202, a Phase II open-label registration-directed trial evaluating VS-7375 900 mg once daily in second- and third-line advanced NSCLC. The study includes a cohort of patients with asymptomatic untreated brain metastases, based on activity observed in preclinical intracranial tumor models. Early data from TARGET-D 101 are expected in H1 2026, with more mature readouts anticipated in H2 2026.

Research context

No approved KRAS G12D-targeted therapy exists, in contrast to the KRAS G12C space where sotorasib (Lumakras, Amgen) and adagrasib (Krazati, Bristol Myers Squibb) are both FDA-approved for previously treated NSCLC. Several companies are pursuing KRAS G12D inhibition. Mirati Therapeutics’ MRTX1133, now part of the Bristol Myers Squibb portfolio following the 2024 acquisition, is in early clinical evaluation. Revolution Medicines (Nasdaq: RVMD) is advancing RMC-9805, a KRAS G12D(OFF) covalent inhibitor, in Phase I/II trials across multiple tumor types. Unlike VS-7375, RMC-9805 targets only the inactive GDP-bound state; Verastem’s compound targets both conformational states, a mechanistic distinction the company argues may translate into more complete pathway suppression, though comparative clinical data do not yet exist.

VS-7375 originated from Verastem’s collaboration with GenFleet Therapeutics, signed in December 2023. Verastem exercised its license in January 2025, securing development and commercialization rights outside mainland China, Hong Kong, Macau, and Taiwan. GenFleet retains rights within those markets, where the compound is designated GFH375. Verastem already markets AVMAPKI/FAKZYNJA CO-PACK in the US, a RAF/MEK inhibitor combination for RAS/MAPK-driven cancers, providing commercial infrastructure relevant to the broader pipeline strategy. The company is pursuing VS-7375 across three tumor types — pancreatic, NSCLC, and colorectal — with registration-directed Phase II trials (TARGET-D 201, 202, and 203, respectively) now active for each.


This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/